These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20425272)

  • 1. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.
    Thomas T; Ginsberg H
    Curr Atheroscler Rep; 2010 Jan; 12(1):58-65. PubMed ID: 20425272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
    Crooke RM; Graham MJ; Lemonidis KM; Whipple CP; Koo S; Perera RJ
    J Lipid Res; 2005 May; 46(5):872-84. PubMed ID: 15716585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
    Reyes-Soffer G; Moon B; Hernandez-Ono A; Dionizovik-Dimanovski M; Jimenez J; Obunike J; Thomas T; Ngai C; Fontanez N; Donovan DS; Karmally W; Holleran S; Ramakrishnan R; Mittleman RS; Ginsberg HN
    Sci Transl Med; 2016 Jan; 8(323):323ra12. PubMed ID: 26819195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs.
    Suzuki H; Aoki T; Tamaki T; Sato F; Kitahara M; Saito Y
    Atherosclerosis; 1999 Oct; 146(2):259-70. PubMed ID: 10532682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
    Myerson M; Ngai C; Jones J; Holleran S; Ramakrishnan R; Berglund L; Ginsberg HN
    J Lipid Res; 2005 Dec; 46(12):2735-44. PubMed ID: 16162940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis.
    Conlon DM; Thomas T; Fedotova T; Hernandez-Ono A; Di Paolo G; Chan RB; Ruggles K; Gibeley S; Liu J; Ginsberg HN
    J Clin Invest; 2016 Oct; 126(10):3852-3867. PubMed ID: 27599291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.
    Telford DE; Lipson SM; Barrett PH; Sutherland BG; Edwards JY; Aebi JD; Dehmlow H; Morand OH; Huff MW
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2608-14. PubMed ID: 16210564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y; Ramakrishnan R; Ginsberg HN
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.